Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sidney V Keisner"'
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 23(1)
Enzalutamide is an androgen receptor antagonist used for the treatment of metastatic castration-resistant prostate cancer. Enzalutamide is classified as a strong cytochrome P450 3A4 inducer, a moderate 2C9 and 2C19 inducer, and a time-dependent induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b9d4ae319d212c6fc09752e520fdee
https://pubmed.ncbi.nlm.nih.gov/26454199
https://pubmed.ncbi.nlm.nih.gov/26454199
Autor:
Sachin R Shah, Sidney V Keisner
Publikováno v:
Drugs. 71(4)
Treatment options for renal cell carcinoma (RCC) have multiplied in the past 5 years. Pazopanib is the third tyrosine kinase inhibitor (TKI) and the sixth targeted therapy that has received US FDA approval for the treatment of advanced or metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3a47f1794846c4f57f288c8c80ac00b
https://pubmed.ncbi.nlm.nih.gov/21395357
https://pubmed.ncbi.nlm.nih.gov/21395357
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 20(1)
The purpose of this study was to evaluate the incidence of acute renal failure (ARF) in patients with mild to moderate renal dysfunction, receiving renally adjusted zoledronic acid (ZA) and compare it to patients with normal baseline renal function,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e1a4210c11cf28ed03244cb788be77
https://pubmed.ncbi.nlm.nih.gov/21197550
https://pubmed.ncbi.nlm.nih.gov/21197550
Publikováno v:
Journal of Clinical Oncology. 28:e15052-e15052
e15052 Background: In AIPC, the combination of docetaxel and prednisone has been shown to increase overall survival and progression free survival. Ketoconazole is considered in patients with AIPC t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8aca4a90c25029d51ea87b2428d122e
https://doi.org/10.1200/jco.2010.28.15_suppl.e15052
https://doi.org/10.1200/jco.2010.28.15_suppl.e15052
Publikováno v:
Journal of Clinical Oncology. 28:e15114-e15114
e15114 Background: The area under the curve (AUC) of K has been shown to be decreased by 83.4% and 95% when administered concurrently with omeprazole and ranitidine, respectively. No published stud...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d38c4c85daf98411873d4bcfe7424e7
https://doi.org/10.1200/jco.2010.28.15_suppl.e15114
https://doi.org/10.1200/jco.2010.28.15_suppl.e15114